Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Picks Up Rights to Nuvation’s Taletrectinib in Europe, Other Regions
Eisai said on January 13 that it has signed an exclusive licensing agreement with US-based Nuvation Bio for the oral ROS1 tyrosine kinase inhibitor taletrectinib, obtaining the rights in Europe and other markets outside the US, China, and Japan. Under…
To read the full story
Related Article
- Eisai, Nuvation Bio’s Taletrectinib Enters EMA Review for ROS1+ NSCLC
March 30, 2026
- Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
BUSINESS
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Lilly Breaks Ground on New Building at Kobe Plant
June 15, 2026
- Shionogi Invests in Reproductive Medicine Startup Dioseve
June 15, 2026
- Chugai Files Tecentriq for Esophageal Cancer
June 15, 2026
- AbbVie Japan Files Rinvoq for Takayasu Arteritis
June 15, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…